330 related articles for article (PubMed ID: 38818288)
1. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges.
Xie C; Alkhouri N; Elfeki MA
World J Hepatol; 2024 May; 16(5):731-750. PubMed ID: 38818288
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.
Chrysavgis LG; Kazanas S; Bafa K; Rozani S; Koloutsou ME; Cholongitas E
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612640
[TBL] [Abstract][Full Text] [Related]
3. Incretin-based investigational therapies for the treatment of MASLD/MASH.
Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Shin S; Kim J; Lee JY; Kim J; Oh CM
J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
[TBL] [Abstract][Full Text] [Related]
5. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
Clin Gastroenterol Hepatol; 2024 Feb; ():. PubMed ID: 38367743
[TBL] [Abstract][Full Text] [Related]
6. Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
Ordóñez-Vázquez AL; Beltrán-Gall SM; Pal SC; Méndez-Sánchez N
Med Sci Monit; 2022 Sep; 28():e938365. PubMed ID: 36093924
[TBL] [Abstract][Full Text] [Related]
7. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
[TBL] [Abstract][Full Text] [Related]
8. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch M; Roden M; Kahl S
Metabolism; 2024 May; ():155937. PubMed ID: 38782182
[TBL] [Abstract][Full Text] [Related]
9. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
[TBL] [Abstract][Full Text] [Related]
10. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.
Akhverdyan N; Wieland A; Sullivan S; Lindsay M; Swartwood S; Arndt G; Kaizer LK; Jensen T
Metab Syndr Relat Disord; 2024 Jun; ():. PubMed ID: 38868900
[No Abstract] [Full Text] [Related]
11. Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
McGlone ER; Tan TM
Peptides; 2024 Jun; 176():171219. PubMed ID: 38615717
[TBL] [Abstract][Full Text] [Related]
12. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
Campbell RK
Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
[TBL] [Abstract][Full Text] [Related]
13. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like Peptide-1 Receptor Agonists-A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD).
Choi E; Ramirez Tovar A; He Z; Soler Rodriguez DM; Vos MB; Arora S; Fadoju D
Children (Basel); 2024 Feb; 11(3):. PubMed ID: 38539310
[TBL] [Abstract][Full Text] [Related]
15. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
[TBL] [Abstract][Full Text] [Related]
16. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.
Newsome PN; Ambery P
J Hepatol; 2023 Dec; 79(6):1557-1565. PubMed ID: 37562748
[TBL] [Abstract][Full Text] [Related]
17. Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study.
Hachuła M; Kosowski M; Basiak M; Okopień B
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37764998
[TBL] [Abstract][Full Text] [Related]
18. The role of incretin hormones and glucagon in patients with liver disease.
Junker AE
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
[TBL] [Abstract][Full Text] [Related]
19. Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Scavo MP; Lisco G; Depalo N; Rizzi F; Volpe S; Arrè V; Carrieri L; Notarnicola M; De Nunzio V; Curri ML; De Pergola G; Piazzolla G; Giannelli G
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338770
[TBL] [Abstract][Full Text] [Related]
20. Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.
Giannakogeorgou A; Roden M
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S52-S75. PubMed ID: 38813830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
